The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.

被引：1
|
作者：
Reinhard, H.
Meyer, S. K.
Bartels, K.
Fischer, R.
Seimetz, D.
Bokemeyer, C.
Atanackovic, D.
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr, Hamburg, Germany
[3] Fresenius Biotech GmbH, Munich, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Catumaxomab - trifunctional anti-EpCAM antibody used to treat malignant ascites
    Bokemeyer, Carsten
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (08) : 1259 - 1269
  • [2] Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Seimetz, Diane
    Lindhofer, Horst
    Bokemeyer, Carsten
    CANCER TREATMENT REVIEWS, 2010, 36 (06) : 458 - 467
  • [3] The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
    Atanackovic, Djordje
    Reinhard, Henrike
    Meyer, Sabrina
    Spoeck, Stefanie
    Grob, Tobias
    Luetkens, Tim
    Yousef, Sara
    Cao, Yanran
    Hildebrandt, York
    Templin, Julia
    Bartels, Katrin
    Lajmi, Nesrine
    Stoiber, Heribert
    Kroeger, Nicolaus
    Atz, Judith
    Seimetz, Diane
    Izbicki, Jakob R.
    Bokemeyer, Carsten
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (12) : 2533 - 2542
  • [4] First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam x Anti-CD3) for Epithelial Ovarian Cancer
    Papanikolaou, Georgios
    Fotopoulou, Christina
    Braicu, Ioana
    Chekerov, Radoslav
    Schmidt, Sven Christian
    Pietzner, Klaus
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2011, 31 (08) : 2603 - 2608
  • [5] Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion
    Sebastian, M.
    Jaeger, M.
    Kiewe, P.
    Schuette, W.
    Wiewrodt, R.
    Lindhofer, H.
    Mueller, B.
    Friccius-Quecke, H.
    Friccius-Quecke, H.
    Schmittel, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study
    Martin Sebastian
    Bernward Passlick
    Hilke Friccius-Quecke
    Michael Jäger
    Horst Lindhofer
    Frank Kanniess
    Rainer Wiewrodt
    Eckhard Thiel
    Roland Buhl
    Alexander Schmittel
    Cancer Immunology, Immunotherapy, 2007, 56 : 1637 - 1644
  • [7] Application of the Trifunctional Antibody Catumaxomab as Part of a Multimodal Approach in Resectable Gastric Cancer is Feasible and Promotes the Development of Tumour-specific Immune Responses
    Atanackovic, D.
    Reinhard, H.
    Schuhmacher, C. P.
    Ridwelski, K.
    Arnold, D.
    Meyer, S. K.
    Bartels, K.
    Fischer, R.
    Seimetz, D.
    Bokemeyer, C. P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S446 - S446
  • [8] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3):: a phase I study
    Sebastian, Martin
    Passlick, Bernward
    Friccius-Quecke, Hilke
    Jaeger, Michael
    Lindhofer, Horst
    Kanniess, Frank
    Wiewrodt, Rainer
    Thiel, Eckhard
    Buhl, Roland
    Schmittel, Alexander
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) : 1637 - 1644
  • [9] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites
    Jaeger, M. J.
    Schoberth, A. M.
    Heiss, M. M.
    Lahr, A.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
    Jaeger, Michael
    Schoberth, Alexandra
    Ruf, Peter
    Hess, Juergen
    Hennig, Michael
    Schmalfeldt, Barbara
    Wimberger, Pauline
    Stroehlein, Michael
    Theissen, Bettina
    Heiss, Markus M.
    Lindhofer, Horst
    CANCER RESEARCH, 2012, 72 (01) : 24 - 32
12345